Concepedia

Author

Michael C. Keefer

University of Rochester

Also Known As

Daniel Kaul, Jennifer A Johnson, Jennifer Kasztejna, Jia Jin  Kee, MICHAEL C. KEEFER, Michael C Keefer, Michael C. Keefer, Michael Keefer, Michael Keefer (review author), Michael C. Keefer

147

Publications

5.4K

Citations

44

H-Index

46

Concepts

All Affiliations

University of RochesterUniversity of Alabama at BirminghamFred Hutch Cancer CenterNational Institute of Allergy and Infectious DiseasesUniversity of Rochester Medical Center
MC

About

Michael C. Keefer is an author at University of Rochester specializing in medicine, hiv, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

1.3K

2

Public Health

3

3

45

3

African American Studies

2

2

35

4

Language Studies

1

1

17

5

Social Sciences

1

1

17

Michael C. Keefer

×

75

Publications

5.1K

Citations

44

H-Index

YearCitations

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

Scott M. Hammer, Magdalena E. Sobieszczyk, Holly Janes,

New England Journal of Medicine

2013

575

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

Wilton B. Williams, Hua-Xin Liao, M. Anthony Moody,

Science

2015

202

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

Spyros A. Kalams, Scott Parker, Marnie Elizaga,

The Journal of Infectious Diseases

2013

193

A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8<sup>+</sup>Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

Thomas G. Evans, Michael C. Keefer, Kent J. Weinhold,

The Journal of Infectious Diseases

1999

173

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers

Robert B. Belshe, Geoffrey J. Gorse, Mark J. Mulligan,

AIDS

1998

171

The Emperor’s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)

Thomas P. Lodise, Susan L. Rosenkranz, Matthew Finnemeyer,

Clinical Infectious Diseases

2019

151

Safety and Immunogenicity of a Canarypox‐Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher‐ and Lower‐Risk Volunteers

Robert B. Belshe, Cladd E. Stevens, Geoffrey J. Gorse,

The Journal of Infectious Diseases

2001

144

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

Thomas G. Evans, M. Juliana McElrath, David C. Montefiori,

Vaccine

2001

138

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

Gavin Churchyard, Cecilia Morgan, Elizabeth M. Adams,

PLoS ONE

2011

137

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Paul A. Goepfert, Bo Fu, Anne-Laure Chabanon,

The Lancet Infectious Diseases

2021

123

Page 1